These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 20497097)

  • 1. Zibotentan for the treatment of castrate-resistant prostate cancer.
    Shepard DR; Dreicer R
    Expert Opin Investig Drugs; 2010 Jul; 19(7):899-908. PubMed ID: 20497097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind, placebo-controlled, randomized Phase II trial.
    James ND; Caty A; Payne H; Borre M; Zonnenberg BA; Beuzeboc P; McIntosh S; Morris T; Phung D; Dawson NA
    BJU Int; 2010 Oct; 106(7):966-73. PubMed ID: 20840318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
    Nelson JB; Fizazi K; Miller K; Higano C; Moul JW; Akaza H; Morris T; McIntosh S; Pemberton K; Gleave M
    Cancer; 2012 Nov; 118(22):5709-18. PubMed ID: 22786751
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Trump DL; Payne H; Miller K; de Bono JS; Stephenson J; Burris HA; Nathan F; Taboada M; Morris T; Hubner A
    Prostate; 2011 Sep; 71(12):1264-75. PubMed ID: 21271613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-endothelin drugs in solid tumors.
    Russo A; Bronte G; Rizzo S; Fanale D; Di Gaudio F; Gebbia N; Bazan V
    Expert Opin Emerg Drugs; 2010 Mar; 15(1):27-40. PubMed ID: 20102289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
    Carducci MA; Jimeno A
    Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
    Edwards J
    Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
    Warren R; Liu G
    Expert Opin Investig Drugs; 2008 Aug; 17(8):1237-45. PubMed ID: 18616419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
    Growcott JW
    Anticancer Drugs; 2009 Feb; 20(2):83-8. PubMed ID: 19065106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atrasentan for metastatic hormone refractory prostate cancer.
    Murphy G
    Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.
    Armstrong AJ; Febbo PG
    Oncologist; 2009 Aug; 14(8):816-27. PubMed ID: 19684076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on castrate-resistant prostate cancer: 2010.
    Lassi K; Dawson NA
    Curr Opin Oncol; 2010 May; 22(3):263-7. PubMed ID: 20177381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
    Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
    J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging therapies in castrate-resistant prostate cancer.
    Lassi K; Dawson NA
    Curr Opin Oncol; 2009 May; 21(3):260-5. PubMed ID: 19363343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
    Jimeno A; Carducci M
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):419-27. PubMed ID: 16001950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atrasentan Abbott.
    Norman P
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1240-8. PubMed ID: 12211423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.